This phase 3 trial is designed to compare loncastuximab tesirine plus rituximab with standard immunochemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.
The median duration of response was not reached in patients with follicular lymphoma or diffuse large B-cell lymphoma.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.
